MCID: CRV033
MIFTS: 44

Cervical Adenosquamous Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenosquamous Carcinoma

MalaCards integrated aliases for Cervical Adenosquamous Carcinoma:

Name: Cervical Adenosquamous Carcinoma 12 15 73
Adenosquamous Cell Carcinoma of the Cervix Uteri 12
Adenosquamous Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5636
NCIt 50 C4519
SNOMED-CT 68 254888007
UMLS 73 C0346202

Summaries for Cervical Adenosquamous Carcinoma

Disease Ontology : 12 A cervical carcinoma that derives from squamous cells and gland-like cells.

MalaCards based summary : Cervical Adenosquamous Carcinoma, also known as adenosquamous cell carcinoma of the cervix uteri, is related to adenocarcinoma and glassy cell variant cervical adenosquamous carcinoma. An important gene associated with Cervical Adenosquamous Carcinoma is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are GPCR Pathway and Focal Adhesion. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cervical Adenosquamous Carcinoma

Diseases related to Cervical Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 28.2 CDKN2A EGFR KDR PTGS2
2 glassy cell variant cervical adenosquamous carcinoma 12.4
3 pulmonary vein stenosis 10.6 KDR PDGFRA
4 lung adenoid cystic carcinoma 10.6 EGFR PDGFRA
5 adenosquamous cell lung carcinoma 10.6 EGFR PDGFRA
6 lacrimal gland mucoepidermoid carcinoma 10.4 CRTC1 MAML2
7 cervicitis 10.4
8 adenosquamous carcinoma 10.4
9 spinal chordoma 10.3 EGFR KDR PDGFRA
10 cutaneous mucoepidermoid carcinoma 10.3 CRTC1 MAML2
11 clear cell hidradenoma 10.3 CRTC1 MAML2
12 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
13 anaplastic oligodendroglioma 10.3 CDKN2A EGFR
14 warthin tumor 10.2 CRTC1 MAML2
15 brain glioma 10.2 EGFR NOTCH1
16 oropharynx cancer 10.2 CDKN2A EGFR
17 lipoadenoma 10.2 CRTC1 MAML2
18 basaloid squamous cell carcinoma 10.2 CDKN2A EGFR
19 peritoneal mesothelioma 10.1 CDKN2A EGFR
20 vulva cancer 10.1 CDKN2A EGFR
21 cervix carcinoma 10.1
22 pre-malignant neoplasm 10.1 CDKN2A EGFR
23 mucinous adenocarcinoma 10.0 CDKN2A EGFR
24 grade iii astrocytoma 10.0 CDKN2A EGFR PDGFRA
25 salivary gland cancer 10.0 CRTC1 EGFR MAML2
26 chordoma 10.0 CDKN2A EGFR PDGFRA
27 bursitis 10.0 KDR PTGS2
28 fibrosarcoma of bone 10.0 CDKN2A KDR PDGFRA
29 plasmablastic lymphoma 10.0 CDKN2A NOTCH1
30 malignant peripheral nerve sheath tumor 10.0 CDKN2A EGFR PDGFRA
31 oral cavity cancer 10.0 CRTC1 EGFR MAML2
32 mucoepidermoid carcinoma 10.0 CRTC1 EGFR MAML2
33 oligodendroglioma 10.0 CDKN2A EGFR PDGFRA
34 brain cancer 9.9 EGFR NOTCH1 PDGFRA
35 gastrointestinal stromal tumor 9.9 CDKN2A EGFR PDGFRA
36 clopidogrel resistance 9.9 KDR PTGS2
37 conn's syndrome 9.8
38 duodenitis 9.8
39 penile cancer 9.8 CDKN2A EGFR
40 bone squamous cell carcinoma 9.7 CDKN2A KDR NOTCH1
41 bowenoid papulosis 9.7 CDKN2A PTGS2
42 pancreas adenocarcinoma 9.7 CDKN2A EGFR NOTCH1
43 balanitis xerotica obliterans 9.7 CDKN2A PTGS2
44 necrotizing sialometaplasia 9.6 CDKN2A CRTC1 MAML2
45 glioblastoma multiforme 9.6 CDKN2A EGFR KDR PDGFRA
46 glioma 9.5 CDKN2A EGFR KDR PDGFRA
47 in situ carcinoma 9.5 CDKN2A EGFR
48 barrett's adenocarcinoma 9.4 CDKN2A PTGS2
49 cervical adenocarcinoma 9.4 CDKN2A EGFR PTGS2
50 oral cancer 9.4 CDKN2A EGFR PTGS2

Graphical network of the top 20 diseases related to Cervical Adenosquamous Carcinoma:



Diseases related to Cervical Adenosquamous Carcinoma

Symptoms & Phenotypes for Cervical Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 EGFR
2 Decreased viability GR00173-A 10.3 PDGFRA
3 Decreased viability GR00221-A-1 10.3 HCK KDR CDKN2A PDGFRA EGFR
4 Decreased viability GR00221-A-2 10.3 HCK KDR
5 Decreased viability GR00221-A-3 10.3 PDGFRA KDR CDKN2A
6 Decreased viability GR00221-A-4 10.3 EGFR PDGFRA HCK KDR CDKN2A
7 Decreased viability GR00402-S-2 10.3 HCK KDR CDKN2A PDGFRA EGFR
8 Synthetic lethal with gemcitabine GR00225-A 8.8 HCK KDR CDKN2A

MGI Mouse Phenotypes related to Cervical Adenosquamous Carcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.11 PDGFRA NOTCH1 PTGS2 CRTC1 KDR EGFR
2 cardiovascular system MP:0005385 10.1 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A
3 hematopoietic system MP:0005397 10.1 PDGFRA NOTCH1 PTGS2 CRTC1 KDR EGFR
4 homeostasis/metabolism MP:0005376 10.08 PDGFRA NOTCH1 PTGS2 HCK CRTC1 KDR
5 endocrine/exocrine gland MP:0005379 10.07 PDGFRA NOTCH1 PTGS2 CRTC1 EGFR CDKN2A
6 immune system MP:0005387 10.06 PDGFRA NOTCH1 PTGS2 CRTC1 KDR EGFR
7 embryo MP:0005380 10.01 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A
8 digestive/alimentary MP:0005381 9.95 NOTCH1 PTGS2 PDGFRA EGFR CDKN2A
9 integument MP:0010771 9.91 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A
10 muscle MP:0005369 9.85 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A
11 liver/biliary system MP:0005370 9.8 PTGS2 KDR NOTCH1 EGFR CDKN2A
12 neoplasm MP:0002006 9.8 PDGFRA NOTCH1 PTGS2 EGFR CDKN2A HCK
13 no phenotypic analysis MP:0003012 9.65 PTGS2 KDR PDGFRA EGFR CDKN2A
14 respiratory system MP:0005388 9.5 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A
15 pigmentation MP:0001186 9.46 PDGFRA NOTCH1 EGFR CDKN2A
16 skeleton MP:0005390 9.17 PDGFRA NOTCH1 PTGS2 KDR EGFR CDKN2A

Drugs & Therapeutics for Cervical Adenosquamous Carcinoma

Drugs for Cervical Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Vinblastine Approved Phase 3 865-21-4 13342 241903
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
10
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
13
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
15
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
16
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Immunoglobulins Phase 3,Phase 2,Phase 1
22 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25
Isophosphamide mustard Phase 3 0
26 Alkylating Agents Phase 3,Phase 2
27 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
28 Folic Acid Antagonists Phase 3,Phase 2
29 Mitogens Phase 3,Phase 2,Phase 1
30 Mitomycins Phase 3
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Dermatologic Agents Phase 3
33 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 3,Phase 2
38 Vitamin B Complex Phase 3,Phase 2
39 Antibiotics, Antitubercular Phase 3,Phase 2
40 Immunoglobulin G Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Antirheumatic Agents Phase 3,Phase 1,Phase 2
44 Antimetabolites Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 2,Phase 1
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2
48 Folate Nutraceutical Phase 3,Phase 2
49 Vitamin B9 Nutraceutical Phase 3,Phase 2
50
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
5 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
9 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
10 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
11 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
12 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
13 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
14 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
15 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
16 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
17 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
18 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
19 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
20 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
21 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
22 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
23 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
24 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
25 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
26 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
27 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
28 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
29 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
30 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
31 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
32 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
33 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
34 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
35 Radiation Therapy in Treating Patients With Cervical Cancer Completed NCT00278304 Phase 2
36 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00101192 Phase 2 cisplatin
37 Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
38 Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
39 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
40 Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
41 Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
42 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 2 Cisplatin;Triapine
43 Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Active, not recruiting NCT01266460 Phase 2
44 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Active, not recruiting NCT01267253 Phase 2 Brivanib Alaninate
45 Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting NCT02257528 Phase 2
46 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Active, not recruiting NCT02921269 Phase 2 Atezolizumab
47 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
48 ADXS11-001 High Dose HPV+ Cervical Cancer Active, not recruiting NCT02164461 Phase 1, Phase 2
49 Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Active, not recruiting NCT01230996 Phase 1, Phase 2 Cisplatin
50 Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Not yet recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin

Search NIH Clinical Center for Cervical Adenosquamous Carcinoma

Genetic Tests for Cervical Adenosquamous Carcinoma

Anatomical Context for Cervical Adenosquamous Carcinoma

MalaCards organs/tissues related to Cervical Adenosquamous Carcinoma:

41
Cervix, Lymph Node, Endothelial

Publications for Cervical Adenosquamous Carcinoma

Articles related to Cervical Adenosquamous Carcinoma:

(show all 11)
# Title Authors Year
1
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
2
A case of melanocytic cervical adenosquamous carcinoma complicated with Cushing's syndrome. ( 29767880 )
2017
3
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
4
Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. ( 22497449 )
2012
5
Duodenal metastasis of cervical adenosquamous carcinoma. ( 22387251 )
2012
6
Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. ( 20855955 )
2010
7
Cutaneous metastases of cervical adenosquamous carcinoma. ( 20633787 )
2010
8
Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. ( 19727809 )
2009
9
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. ( 19563658 )
2009
10
Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. ( 17666630 )
2007
11
Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. ( 10684719 )
2000

Variations for Cervical Adenosquamous Carcinoma

Expression for Cervical Adenosquamous Carcinoma

Search GEO for disease gene expression data for Cervical Adenosquamous Carcinoma.

Pathways for Cervical Adenosquamous Carcinoma

Pathways related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 CDKN2A EGFR KDR NOTCH1 PDGFRA PTGS2
2
Show member pathways
12.66 EGFR HCK KDR PDGFRA PTGS2
3 12.55 CDKN2A EGFR NOTCH1 PDGFRA PTGS2
4
Show member pathways
12.46 EGFR KDR MAML2 NOTCH1 PDGFRA PTGS2
5
Show member pathways
12.39 CDKN2A EGFR KDR NOTCH1 PDGFRA
6 12.17 CDKN2A CRTC1 PDGFRA
7
Show member pathways
12.14 EGFR HCK KDR
8
Show member pathways
12.06 EGFR PDGFRA PTGS2
9 11.9 EGFR KDR PDGFRA
10
Show member pathways
11.87 EGFR KDR PDGFRA
11 11.83 CDKN2A EGFR NOTCH1 PDGFRA PTGS2
12 11.75 CDKN2A EGFR PDGFRA
13 11.73 EGFR HCK KDR PDGFRA
14 11.38 KDR NOTCH1 PDGFRA
15 11.34 CDKN2A EGFR PDGFRA
16 11.26 KDR MAML2 NOTCH1
17
Show member pathways
11.22 EGFR KDR
18 11.17 EGFR KDR PDGFRA
19 10.98 MAML2 NOTCH1
20 10.92 KDR PDGFRA
21 10.87 KDR NOTCH1 PDGFRA PTGS2

GO Terms for Cervical Adenosquamous Carcinoma

Cellular components related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.61 CDKN2A CRTC1 EGFR HCK KDR MAML2
2 receptor complex GO:0043235 8.92 EGFR KDR NOTCH1 PDGFRA

Biological processes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.98 CDKN2A CRTC1 EGFR MAML2 NOTCH1
2 cell differentiation GO:0030154 9.97 EGFR HCK KDR NOTCH1 PDGFRA
3 protein phosphorylation GO:0006468 9.91 EGFR HCK KDR PDGFRA
4 phosphorylation GO:0016310 9.89 CDKN2A EGFR HCK KDR PDGFRA
5 viral process GO:0016032 9.85 CRTC1 HCK KDR PDGFRA
6 angiogenesis GO:0001525 9.8 KDR NOTCH1 PTGS2
7 negative regulation of apoptotic process GO:0043066 9.8 EGFR HCK KDR PDGFRA PTGS2
8 regulation of cell proliferation GO:0042127 9.76 EGFR HCK NOTCH1 PTGS2
9 positive regulation of MAPK cascade GO:0043410 9.75 EGFR KDR PDGFRA
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 EGFR KDR NOTCH1 PDGFRA
11 negative regulation of signal transduction GO:0009968 9.71 EGFR KDR PDGFRA
12 lung development GO:0030324 9.69 EGFR NOTCH1 PDGFRA
13 positive regulation of cell migration GO:0030335 9.67 EGFR KDR NOTCH1 PDGFRA
14 positive regulation of kinase activity GO:0033674 9.65 EGFR KDR PDGFRA
15 positive regulation of DNA replication GO:0045740 9.63 EGFR PDGFRA
16 cellular response to reactive oxygen species GO:0034614 9.63 EGFR PDGFRA
17 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.62 KDR PTGS2
18 positive regulation of vasoconstriction GO:0045907 9.61 EGFR PTGS2
19 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.6 KDR NOTCH1
20 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.59 EGFR PTGS2
21 positive regulation of transcription of Notch receptor target GO:0007221 9.56 MAML2 NOTCH1
22 protein autophosphorylation GO:0046777 9.56 EGFR HCK KDR PDGFRA
23 somatic stem cell division GO:0048103 9.52 CDKN2A NOTCH1
24 peptidyl-tyrosine autophosphorylation GO:0038083 9.5 EGFR HCK KDR
25 peptidyl-tyrosine phosphorylation GO:0018108 9.46 EGFR HCK KDR PDGFRA
26 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 EGFR HCK KDR PDGFRA
27 positive regulation of cell proliferation GO:0008284 9.1 EGFR HCK KDR NOTCH1 PDGFRA PTGS2

Molecular functions related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.78 EGFR HCK KDR PDGFRA
2 kinase activity GO:0016301 9.77 CDKN2A EGFR HCK KDR PDGFRA
3 transmembrane signaling receptor activity GO:0004888 9.76 EGFR KDR NOTCH1 PDGFRA
4 MAP kinase kinase kinase activity GO:0004709 9.58 EGFR KDR PDGFRA
5 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 EGFR KDR
6 mitogen-activated protein kinase kinase binding GO:0031434 9.43 EGFR KDR PDGFRA
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.32 KDR PDGFRA
8 vascular endothelial growth factor binding GO:0038085 9.16 KDR PDGFRA
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KDR PDGFRA
10 protein tyrosine kinase activity GO:0004713 8.92 EGFR HCK KDR PDGFRA

Sources for Cervical Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....